Dabigatran ethyl ester hydrochloride is a pharmaceutical intermediate and prodrug of dabigatran, a direct thrombin inhibitor. It is used in the synthesis and research of anticoagulants for preventing and treating thromboembolic disorders, such as stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also applied in the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), including post-orthopedic surgery prophylaxis (e.g., hip or knee replacement). As an alternative to warfarin, it provides predictable anticoagulation without frequent monitoring. Its oral bioavailability and rapid conversion to the active form support long-term management of clotting disorders. This high-purity compound is supplied for laboratory, research, and manufacturing applications.